Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tanzania Consults On East African Community Guidelines, Including For Biosimilars

Executive Summary

The Tanzanian drug regulator is holding a stakeholder workshop on Jan. 25 to discuss the adoption of various guidelines drafted by medicines experts within the East African Community network. On the list of documents to be discussed is a draft guideline on the registration of biosimilars.

You may also be interested in...



Plans For East African Drug Regulator Begin To Take Shape

A report by the European Medicines Agency and the regulators from the East African Community has outlined the possible shape of a regional regulator in east Africa.

ICH Makes Progress On Tackling Safety Data ‘Overload’

Changes to an ICH guideline could help drug companies that are being deluged with post-approval safety information to cut down on noisy, low-value data.

EMA To Consider How To Deliver Drug Risks Information Via Digital Formats

European Medicines Agency plans to finalize changes to its guideline on additional risk minimization measures and then establish a new drafting group on digitalization of education materials.

Topics

UsernamePublicRestriction

Register

PS122271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel